On May 15, 2025 Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, reported that the latest data from eight hematologic malignancy clinical trials will be presented at the 2025 European Hematology Association (EHA) (Free EHA Whitepaper) Congress and the 18th International Conference on Malignant Lymphoma (ICML) (Press release, Dizal Pharma, MAY 15, 2025, View Source [SID1234653193]). Notably, Dizal’s two investigational drugs in lymphoma—golidocitinib and DZD8586—have collectively secured three oral presentations at the upcoming American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, EHA (Free EHA Whitepaper) Congress and ICML.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Golidocitinib and DZD8586 are core assets in our hematologic malignancy pipeline. Accumulating clinical data continue to validate their clinical benefits to patients and attracted community’s attention," said Xiaolin Zhang, PhD, CEO of Dizal.
A high proportion of PTCL patients who achieved tumor response with first-line standard therapy will relapse. Approximately 40% of patients with complete response (CR) and 80% with partial response (PR) experience disease progression within 2 years after initial tumor response. The prognosis of these relapsed patients is very poor. Currently, there is no standard maintenance therapy available.
The latest 2-year follow-up data from JACKPOT26, a prospective, multicenter Phase II study of golidocitinib, will be presented at both the upcoming EHA (Free EHA Whitepaper) Congress and ICML, where it has been selected for an oral presentation. This study explored golidocitinib as a maintenance therapy for peripheral T-cell lymphoma (PTCL) patients who achieved tumor response after first-line systemic therapy. The results showed that with more than 2 years follow-up, golidocitinib continued to demonstrate a promising effect on maintaining and enhancing tumor response in patients with PTCL post first-line therapies, with a manageable safety profile.
Initial positive results of Golidocitinib in combination with CHOP in 1st line PTCL patients will be reported during these meetings. In addition, Dizal will present results for golidocitinib in rare T-cell lymphoma subtypes, including relapsed/refractory T-cell large granular lymphocyte leukemia (r/r T-LGLL), monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL).
Two studies of DZD8586 have been selected for presentation at ASCO (Free ASCO Whitepaper), EHA (Free EHA Whitepaper), and ICML. The safety and efficacy analysis of Phase I/II studies of DZD8586 in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients with prior treatment using covalent and/or non-covalent BTK inhibitors and BTK degraders has been accepted for oral presentation at both ASCO (Free ASCO Whitepaper) and ICML. The study results showed DZD8586 exhibited significant anti-tumor activities with well-tolerated safety profile in these heavily pre-treated CLL/SLL patients.
Results of a Phase II study of DZD8586 as monotherapy in relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) will be reported for the first time at the 2025 EHA (Free EHA Whitepaper) Congress. DZD8586 showed promising anti-tumor activity and a manageable safety profile.
Dizal presentation details during 2025 ICML、EHA：
Lead Author
Abstract Title
Presentation Details
Prof. Jie Jin
Maintenance Therapy of Golidocitinib, a
JAK1 Selective Inhibitor, in Patients with
Peripheral T Cell Lymphomas after First-
line Systemic Therapy: Updates of the
Phase 2 Study (JACKPOT26)
Abstract#167
ICML Oral Presentation
June 21, 2025, 10 :35 (CEST)
Abstract # PS1937
EHA Poster Session
June 14, 2025, 18 :30-19 :30 (CEST)
Prof. Jianyong Li
Phase 1/2 Studies of DZD8586 in
CLL/SLL Patients after Covalent or Non-
covalent BTK Inhibitors and BTK
Degraders
Abstract#146
ICML Oral Presentation
June 19, 2025, 17 :35 (CEST)
Abstract #PF570
EHA Poster Session
June 13, 2025, 18 :30-19 :30 (CEST)
Prof. Lugui Qiu
Phase 2 Study of DZD8586, a Non-
Covalent BBB Penetrant LYN/BTK Dual
Inhibitor, as Monotherapy in
Relapsed/Refractory Diffuse Large B-
Cell Lymphoma (r/r DLBCL) (TAI-SHAN9)
Abstract # PF962
EHA Poster Session
June 13, 2025, 18 :30-19 :30 (CEST)
Abstract #820
ICML Online Publication
June 15, 2025, 23 :59 (CEST)
Prof. Shuhua Yi
Golidocitinib Monotherapy in the
Treatment of Refractory/Relapsed
Indolent T/NK-Cell Lymphoma:
Preliminary Results from T-LGLL Cohort
Abstract # PF908
EHA Poster Session
June 13, 2025, 18 :00-19 :30 (CEST)
Abstract #750
ICML Online Publication
June 15, 2025, 23 :59 (CEST)
Prof. Wei Zhang
Golidocitinib Combined with CHOP in
Newly-Diagnosed Peripheral T-Cell
Lymphoma: Preliminary Results from a
Phase 1/2 Clinical Trial
Abstract # PB3228
EHA Online Publication
May 14, 2025, 15:30 (CEST)
Abstract #751
ICML Online Publication
June 15, 2025, 23 :59 (CEST)
Prof. Huiqiang Huang
Real-World Study of Golidocitinib for the
Treatment of Relapsed or Refractory
Peripheral T-Cell Lymphoma:
Retrospective Data from Medical Centers
in China
Abstract # PB3198
EHA Online Publication
May 14, 2025, 15:30 (CEST)
Abstract #756
ICML Online Publication
June 15, 2025, 23 :59 (CEST)
Prof. Wenyu Li
Golidocitinib Combination Therapy as
First-Line Treatment in PTCL:
Retrospective Data from a Single Centre
Abstract # PB3297
EHA Online Publication
May 14, 2025, 15 :30 (CEST)
Prof. Li Wang
Golidocitinib Combined with CHOP in
Treatment-Naïve Monomorphic
Epitheliotropic Intestinal T-Cell
Lymphoma: preliminary results from a
phase 2 multicenter, single-arm GOAL
study
Abstract # PB3256
EHA Online Publication
May 14, 2025, 15 :30 (CEST)